

MDIC Draft
Tumor Suppressor Gene List
For Public Comment

Gene	Indications	Therapies	Clinical evidence source
BRCA1	breast, ovarian, prostate	PARP inhibitors	OncoKB Level 1
BRCA2	breast, ovarian, prostate	PARP inhibitors	OncoKB Level 1
TSC1	glioma	Everolimus	OncoKB Level 1
TSC2	glioma	Everolimus	OncoKB Level 1
ATM	breast, ovarian, prostate	PARP inhibitors	Phase 3 trials - enrollment
TP53	High pan-tumor prevalence	multiple therapies (e.g. multiple therapies including MDM2 inhibitors inhibitors)	Phase 3 trials - enrollment
PTEN	Breast cancer	PI3K inhibitors	Phase 3 trials - enrollment
MLH1	MSI-high tumors (multiple indications)	I/O agents + other CRC therapies	NCNN guideline
PMS2	MSI-high tumors (multiple indications)	I/O agents + other CRC therapies	NCNN guideline
MSH2	MSI-high tumors (multiple indications)	I/O agents + other CRC therapies	NCNN guideline
MSH6	MSI-high tumors (multiple indications)	I/O agents + other CRC therapies	NCNN guideline